This 2002 text surveys the current status and future directions of stroke pathophysiology, diagnosis and treatment.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Part I: 1. Zinc toxicity in the ischemic brain; 1. 2. Central nervous system ischemia: diversity among the caspases; Part II: 3. Peroxynirite and injury to the vasculature and central nervous system in stroke and neurodegeneration; 4. Interaction between inducible nitric oxide and cyclooxygenase-2 in ischemic brain injury; 5. Mechanisms of ischemic tolerance; 6. Clinically-tolerated NMDA receptor antagonists and newly cloned NMDA receptor subunits that mimic them; Part III: 7. Cell death programs in neutral development and disease; 8. Apoptotic gene expression in brain Ischemia and ischemic tolerance; 9. Cellular mechanisms of white matter ischemia: what can we learn from culture models?; Part IV: 10. Astrocytes in ischemic stroke; 11. Aquaporin-4 water channels and brain edema; 12. Neuroprotection with tetracyclines in brain ischemia models; 13. Spreading depression: a teleologic means for self-protection from brain ischemia; Part V: 14. The role of matrix metalloproteinases and urokinase in blood-brain barrier damage with thrombolysis; 15. Does brain nitric oxide generation influence tissue oxygenation after severe human subarachnoid hemorrhage?; 16. Tissue plasminogen activator and hemorrhagic brain injury; 17. Dynamics of infarct evolution after permanent and transient focal brain ischemia in mice; Part VI: 18. Inflammation and stroke: benefits or harm?; 19. TNF-a and ceramide are involved in the mediation of neuronal tolerance to brain ischemia; 20. Sites and mechanisms of IL-1 action in ischemic and excitotoxic brain damage; 21. Protease generation, inflammation and cerebral microvascular activation; Part VII: 22. Adenoviral vectors for gene therapy in stroke; 23. Gene transfer of glial cell line-derived neurotrophic factor prevents ischemic brain injury; 24. Vasomotor effects of nitric oxide, superoxide dismutases and calcitonin gene-related peptide; Part VIII: 25. Transplantation of neural stem cells: cellular and gene therapy in pediatric hypoxic-ischemic brain injury; 26. Neural plasticity after cerebral ischemia; 27. Environmental effects on recovery after stroke; Part IX: 28. Magnetic resonance imaging in stroke trials; 29. Disappearing deficits and disappearing lesions: diffusion/perfusion MRI in TIA and intra-arterial thrombolysis; 30. Diffusion and perfusion magnetic resonance imaging in the evaluation of acute ischemic stroke; 31. Early recanalization in acute ischemic stroke saves tissue at risk defined by stroke magnetic resonance imaging; Part X: 32. Vascular factors in Alzheimer's disease; 33. Beyond neuroprotection: the protection of axons and oligodendrocytes in cerebral ischemia; 34. Combining neuroprotection with thrombolysis: how to translate laboratory success to our clinical trials; 35. Prospects for improved neuroprotection trials in stroke; 36. Basic research and stroke therapeutics: what have we learned?
Part I: 1. Zinc toxicity in the ischemic brain; 1. 2. Central nervous system ischemia: diversity among the caspases; Part II: 3. Peroxynirite and injury to the vasculature and central nervous system in stroke and neurodegeneration; 4. Interaction between inducible nitric oxide and cyclooxygenase-2 in ischemic brain injury; 5. Mechanisms of ischemic tolerance; 6. Clinically-tolerated NMDA receptor antagonists and newly cloned NMDA receptor subunits that mimic them; Part III: 7. Cell death programs in neutral development and disease; 8. Apoptotic gene expression in brain Ischemia and ischemic tolerance; 9. Cellular mechanisms of white matter ischemia: what can we learn from culture models?; Part IV: 10. Astrocytes in ischemic stroke; 11. Aquaporin-4 water channels and brain edema; 12. Neuroprotection with tetracyclines in brain ischemia models; 13. Spreading depression: a teleologic means for self-protection from brain ischemia; Part V: 14. The role of matrix metalloproteinases and urokinase in blood-brain barrier damage with thrombolysis; 15. Does brain nitric oxide generation influence tissue oxygenation after severe human subarachnoid hemorrhage?; 16. Tissue plasminogen activator and hemorrhagic brain injury; 17. Dynamics of infarct evolution after permanent and transient focal brain ischemia in mice; Part VI: 18. Inflammation and stroke: benefits or harm?; 19. TNF-a and ceramide are involved in the mediation of neuronal tolerance to brain ischemia; 20. Sites and mechanisms of IL-1 action in ischemic and excitotoxic brain damage; 21. Protease generation, inflammation and cerebral microvascular activation; Part VII: 22. Adenoviral vectors for gene therapy in stroke; 23. Gene transfer of glial cell line-derived neurotrophic factor prevents ischemic brain injury; 24. Vasomotor effects of nitric oxide, superoxide dismutases and calcitonin gene-related peptide; Part VIII: 25. Transplantation of neural stem cells: cellular and gene therapy in pediatric hypoxic-ischemic brain injury; 26. Neural plasticity after cerebral ischemia; 27. Environmental effects on recovery after stroke; Part IX: 28. Magnetic resonance imaging in stroke trials; 29. Disappearing deficits and disappearing lesions: diffusion/perfusion MRI in TIA and intra-arterial thrombolysis; 30. Diffusion and perfusion magnetic resonance imaging in the evaluation of acute ischemic stroke; 31. Early recanalization in acute ischemic stroke saves tissue at risk defined by stroke magnetic resonance imaging; Part X: 32. Vascular factors in Alzheimer's disease; 33. Beyond neuroprotection: the protection of axons and oligodendrocytes in cerebral ischemia; 34. Combining neuroprotection with thrombolysis: how to translate laboratory success to our clinical trials; 35. Prospects for improved neuroprotection trials in stroke; 36. Basic research and stroke therapeutics: what have we learned?
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
